- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2012–2022 · program · P01
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2022 · program · P01
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2022 · program · P01
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2022 · research · R01
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · research · R01
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2022 · research · R01
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2022 · program · P01
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · program · P01
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2022 · research · R01
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2022 · research · R01
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · program · P01
Project 1: Development of pharmacologic strategies to degrade mutant EGFR.
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · program · P01
Core B: Structure and Biochemistry
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · program · P01
Core A: Medicinal Chemistry
Nathanael Schiander Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · program · P01
Project 2: Identification of combination therapy for KRAS-driven lung cancers.
William C. Hahn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · program · P01
Core C: Animal Modeling and Preclinical Therapeutics
Kwok Kin Wong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · program · P01
Project 3: Targeting transcriptional mechanisms of therapeutic resistance in non-small cell lung cancer.
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2012–2023 · program · P01
Core D: Program Administration
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2022 · research · R01
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2022 · program · P01
Integrative Oncogenomics of Multiple Myeloma
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2021 · research · R01
Targetable Immune Evasion Pathways in Hodgkin Lymphoma
Margaret A Shipp · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · research · R01
Energy Expenditure and Metabolic Effects through Brown/Beige Adipose Clk2 Kinase
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2022 · research · R01
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2027 · research · R01
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2022 · research · R01
Targetable Immune Evasion Pathways in Hodgkin Lymphoma
Margaret A Shipp · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2021 · research · R01
Energy Expenditure and Metabolic Effects through Brown/Beige Adipose Clk2 Kinase
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2027 · research · R01
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2021 · research · R01
Energy Expenditure and Metabolic Effects through Brown/Beige Adipose Clk2 Kinase
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2021 · research · R01
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2021 · research · R01
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2021 · research · R01
Targetable Immune Evasion Pathways in Hodgkin Lymphoma
Margaret A Shipp · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2021 · research · R01
Targetable Immune Evasion Pathways in Hodgkin Lymphoma
Margaret A Shipp · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2022 · program · P01
Integrative Oncogenomics of Multiple Myeloma
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2021 · research · R01
Targetable Immune Evasion Pathways in Hodgkin Lymphoma
Margaret A Shipp · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · research · R01
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2022 · program · P01
Integrative Oncogenomics of Multiple Myeloma
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2027 · research · R01
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2021 · research · R01
Energy Expenditure and Metabolic Effects through Brown/Beige Adipose Clk2 Kinase
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Integrative Oncogenomics of Multiple Myeloma
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2022 · research · R01
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2022 · research · R01
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
